Direct answer: FDA premarket pathways for medical devices differ by device risk class and the availability of a predicate. 510(k) clearance applies to most Class II devices (and some Class I) that are substantially equivalent to a marketed predicate. De Novo classification applies to novel low-to-moderate risk devices without a usable predicate. Premarket Approval (PMA) is required for Class III devices, where the FDA independently determines safety and effectiveness. The pathway determines both your evidence burden and the marketing term you are legally permitted to use: "cleared" for 510(k), "De Novo granted" for De Novo, and "approved" for PMA. (As of July 2026.)
Choosing the right FDA pathway is one of the earliest and most consequential regulatory decisions a medical device company makes. Get it right and you build toward a realistic clearance or approval timeline. Get it wrong and you can spend years and significant capital on a PMA for a device that qualified for 510(k), or submit a 510(k) for a device with no usable predicate and receive a not-substantially-equivalent (NSE) determination.
For founders and marketing leaders, pathway selection also has direct implications for your launch narrative. The word you are permitted to use, the evidentiary story you can tell, and how quickly you can go to market all flow from which pathway you take.
This article explains all three pathways, compares them on the dimensions that matter for business planning, and explains what each outcome means for your marketing program.
The Framework: Device Class Drives Pathway
FDA device pathways map to the three-class risk system established in 21 CFR Part 860 (https://www.law.cornell.edu/cfr/text/21/part-860). Understanding the class structure is the starting point for pathway selection.
Class I. Lowest risk. Subject to general controls only (establishment registration, device listing, quality system, labeling, adverse event reporting). Most Class I devices are exempt from premarket submission. Examples: elastic bandages, examination gloves, tongue depressors.
Class II. Moderate risk. Subject to general controls plus special controls (performance standards, post-market surveillance, patient registries, guidance documents, or other measures sufficient to provide reasonable assurance of safety and effectiveness). Most Class II devices reach market via 510(k). Examples: glucose monitors, infusion pumps, diagnostic ultrasound, many software as a medical device (SaMD) products.
Class III. Highest risk. Devices that support or sustain human life, are substantially important to preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is required unless the device type has been down-classified. Examples: implantable cardiac pacemakers, cochlear implants, mechanical heart valves.
The 510(k): Substantial Equivalence
Who it is for: Class II device companies that can identify a legally marketed predicate device with the same intended use.
What the FDA evaluates: Whether your device is substantially equivalent to the predicate: same intended use, and either the same technological characteristics, or different technological characteristics that do not raise new questions of safety and effectiveness. The FDA does not independently evaluate whether the device is safe and effective in an absolute sense.
Statutory basis: Section 510(k) of the FD&C Act, 21 U.S.C. 360(k) (https://www.law.cornell.edu/uscode/text/21/360); implementing regulations at 21 CFR Part 807, Subpart E (https://www.law.cornell.edu/cfr/text/21/part-807/subpart-E).
Outcome: Substantial equivalence (SE) order, commonly called a clearance. The correct marketing term is "FDA cleared."
Evidence standard: Performance testing (bench, animal, or clinical as needed) sufficient to support the substantial equivalence comparison. The bar is relative to the predicate, not an absolute safety and effectiveness standard. For many Class II devices, bench testing and biocompatibility data are sufficient; clinical data is required only when needed to support the equivalence finding.
Timeline: FDA's MDUFA decision goal is 90 FDA review days. Under MDUFA V, FDA's Total Time to Decision goal is 112 calendar days for FY2025 through FY2027. Including acceptance review and common Additional Information (AI) request cycles, realistic elapsed timelines run several months for well-prepared submissions on established device types.
Cost: Highly variable. User fees for 510(k), De Novo, and PMA submissions are set annually under MDUFA V (fiscal years 2023 through 2027); the current fee schedule is published on FDA's MDUFA fees page (https://www.fda.gov/industry/fda-user-fee-programs/medical-device-user-fee-amendments-mdufa-fees). Total all-in cost including testing, regulatory consultant time, and submission preparation varies widely with device complexity.
Marketing implication: Use "FDA cleared" or "510(k) cleared." Never use "FDA approved" for a 510(k) device. 21 CFR 807.97 (https://www.law.cornell.edu/cfr/text/21/807.97) makes this explicit. See our full explainer on FDA cleared vs FDA approved medical device marketing.
De Novo: Novel Devices Without a Predicate
Who it is for: Devices that are novel (no usable 510(k) predicate exists) and low-to-moderate risk (would be Class I or Class II if classified, not Class III).
What the FDA evaluates: Whether the device type can be classified into Class I or Class II based on general controls alone (Class I) or general controls plus special controls (Class II), and whether those controls are sufficient to provide reasonable assurance of safety and effectiveness.
Statutory basis: Section 513(f)(2) of the FD&C Act, 21 U.S.C. 360c(f)(2) (https://www.law.cornell.edu/uscode/text/21/360c); FDA's De Novo program page is at https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request.
Outcome: A De Novo classification order. The device is classified (usually into Class I or Class II). Importantly, a De Novo grant creates a new predicate: other manufacturers can now cite your device in their own 510(k) submissions. The correct marketing term is "De Novo granted" or "FDA De Novo authorized." Neither "cleared" nor "approved" is accurate.
Evidence standard: Similar in some respects to a 510(k) but must stand on its own without a predicate comparison. Requires a showing that proposed special controls (if Class II) or general controls (if Class I) are sufficient to reasonably assure safety and effectiveness. The FDA evaluates the De Novo request using an absolute standard, not a comparative one.
Timeline: The FDA's review goal for De Novo requests is 150 days. In practice, total timelines are often longer. De Novo is a less frequently used pathway (typically a few hundred requests per year versus several thousand 510(k)s), so less predictable timeline benchmarking is available.
Cost: De Novo user fees are separate from 510(k) fees and generally higher. The De Novo process also requires a more extensive regulatory strategy and evidence package than a routine 510(k), which increases preparation costs.
Marketing implication: Do not describe a De Novo device as "FDA cleared" or "FDA approved." Use "De Novo granted," "received De Novo classification from the FDA," or "FDA De Novo authorized." The strategic upside is significant: your device may have no direct competitor with equivalent regulatory status, which gives your marketing team a genuine differentiator. See our article on De Novo and PMA launch marketing for how to position this.
PMA: The Highest Standard of FDA Review
Who it is for: Class III devices: those supporting or sustaining life, substantially important to preventing impairment, or presenting a potential unreasonable risk.
What the FDA evaluates: Valid scientific evidence (typically including clinical data from well-controlled clinical studies) demonstrating reasonable assurance that the device is safe and effective for its intended use. This is an absolute standard, not a comparative one.
Statutory basis: Section 515 of the FD&C Act, 21 U.S.C. 360e (https://www.law.cornell.edu/uscode/text/21/360e); implementing regulations at 21 CFR Part 814 (https://www.law.cornell.edu/cfr/text/21/part-814). The FDA's PMA program page is at https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma.
Outcome: A PMA approval order. The correct marketing term is "FDA approved."
Evidence standard: The highest in the device regulatory system. PMA applications typically require well-controlled clinical studies demonstrating safety and effectiveness, comprehensive manufacturing information, labeling, and a rigorous safety and effectiveness summary. The FDA may convene an advisory panel to evaluate the application.
Timeline: The FDA's statutory review period for a PMA is 180 FDA-days, but the actual time from submission to approval is almost always longer due to the clinical data requirements, AI cycles, and potential panel review. Realistic timelines from first clinical enrollment to PMA approval can span several years.
Cost: PMA is the most expensive pathway by a significant margin. User fees, clinical trial costs, the burden of manufacturing compliance, and the extended timeline all contribute to substantial total development costs for complex devices.
Marketing implication: "FDA approved" is legally accurate and carries the highest evidentiary weight of any device marketing claim. The strategic challenge is that most PMA devices are in clinical categories where claims must be tightly managed against the approved indications. Expanded indication claims require PMA supplements (21 CFR 814.39, https://www.law.cornell.edu/cfr/text/21/814.39). See our article on De Novo and PMA launch marketing for PMA-specific claim guidance.
Side-by-Side Comparison
| Dimension | 510(k) | De Novo | PMA |
|---|---|---|---|
| Device risk class | Primarily Class II (some Class I) | Class I or II (novel) | Class III |
| Predicate required | Yes | No | No |
| Evidence standard | Substantial equivalence to predicate | General and/or special controls sufficient | Valid scientific evidence of safety and effectiveness |
| Clinical data typically required | Rarely | Sometimes | Usually |
| FDA review goal | 90 FDA review days (MDUFA V TTD goal 112 calendar days, FY2025-2027) | 150 days | 180 FDA review days (statutory) |
| Realistic timeline | Several months to a year | 1 to 2 years (estimated) | Multiple years |
| Marketing term | "FDA cleared" | "De Novo granted" / "FDA De Novo authorized" | "FDA approved" |
| Creates new predicate for others? | Yes (for subsequent 510(k)s) | Yes | No (PMA supplements required for modifications) |
| Relative user fee | Moderate | Higher than 510(k) | Highest |
A Fourth Option: 510(k)-Exempt
Many Class I devices, and a subset of Class II devices, do not require any premarket submission. These devices are 510(k)-exempt by regulation (the exemptions are device-type specific, listed in 21 CFR Parts 862 through 892). Exempt does not mean unregulated: general controls, establishment registration, device listing, and quality system requirements still apply. But no premarket submission is required before marketing.
Marketing implication: Do not describe a 510(k)-exempt device as "FDA cleared" or "FDA approved." No clearance was granted. The accurate statement is that the device is a Class I (or Class II) device exempt from 510(k) requirements. See our full article on FDA cleared vs FDA approved medical device marketing for the exempt-device framing.
How Pathway Choice Affects Your Launch Marketing
Pathway choice shapes your launch narrative before you file a single page of documentation.
A 510(k) submission typically moves faster than PMA, which means earlier revenue and an earlier marketing launch. The "cleared" story is also familiar to hospital procurement teams, and the substantial equivalence framework gives you built-in language: your device is at least as safe and effective as the named predicate, with specified improvements.
A De Novo grant is a rarer credential. Your device has no cleared peer in the 510(k) database. The FDA evaluated it on an absolute basis and concluded that the controls you proposed are sufficient to assure safety and effectiveness. That is a story worth telling, and the lack of predicate competition can be a genuine marketing differentiator if positioned correctly.
A PMA approval carries the most regulatory weight of the three and supports claims that no 510(k) or De Novo device can make: the FDA independently determined this device is safe and effective. For Class III devices, that is the commercial headline.
The common failure across all three is using the wrong term. "Approved" for a cleared device, "cleared" for a De Novo device, or "approved" for a device still under PMA review are all misbranding risks under Section 502(a) of the FD&C Act (21 U.S.C. 352, https://www.law.cornell.edu/uscode/text/21/352).
Buzzbox Media has spent over 15 years helping medtech companies translate regulatory milestones into marketing programs that hold up to scrutiny. If your device is approaching clearance, a De Novo grant, or PMA approval and you want to build the launch marketing right from day one, start with a 30-minute call at https://www.buzzboxmedia.com/book.